|
|
|
|
|
|
|
||
Address correspondence to F. Javier Casado, Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Avda Diagonal, 645, 08071 Barcelona, Spain. Fax: 34 934021559; email: fcasado{at}ub.edu
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
) agents. Nucleoside uptake rates and nucleoside transporter protein and mRNA levels were assessed. The signal transduction pathways used by the proliferative stimuli were analyzed. We found that glucocorticoids induce an increase in sodium-dependent, concentrative nucleoside transport rates and in protein and mRNA levels of both rCNT2 and rCNT1, with negligible effects on the equilibrative transporters. EGF and TGF- induce an increase in the equilibrative transport rate, mostly accounted for by an increase in rENT1 activity and mRNA levels, rENT2 mRNA levels remaining unaltered. This effect is mimicked by another proliferative stimulus that functions as an in vitro model of epithelial wounding. Here, rENT1 activity and mRNA levels are also increased, although the signal transduction pathways used by the two stimuli are different. We concluded that differentiation of rat intestinal epithelial cells is accompanied by increased mature enterocyte features, such as concentrative nucleoside transport (located at the brush border membrane of the enterocyte), thus preparing the cell for its ultimate absorptive function. A proliferative stimulus induces the equilibrative nucleoside activities (mostly through ENT1) known to be located at the basolateral membrane, allowing the uptake of nucleosides from the bloodstream for the increased demands of the proliferating cell.
Key Words: drug bioavailability • cell differentiation • adenosine • concentrative transport • equilibrative transport
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
; Casado et al., 2002).
There are two main families of nucleoside transporters, concentrative (CNT) and equilibrative (ENT) transporters (Griffith and Jarvis, 1996; Ritzel et al., 1998; Pastor-Angalda and Baldwin, 2001). Concentrative nucleoside transport activities have been identified in intestinal epithelial cells in several species, including mouse (Vijayalakshmi and Belt, 1988), rat (Iseki et al., 1996), human (Chandrasena et al., 1997; Patil and Unadkat, 1997), and pig (Scharrer et al., 2002). These activities, at least in humans, seem to follow a proximal-to-distal gradient, with maximal transport rates in the jejunum (Ngo et al., 2001). Alongside this activity, the mRNA and protein of the pyrimidine-preferring CNT1 tansporter (Huang et al., 1994) and the purine-preferring CNT2 transporter (Ritzel et al., 1998; Valdés et al., 2000) have also been detected in the small intestine. In the kidney, the pattern of nucleoside transporter expression appears to be more complex, since CNT2 has been detected in human kidney (Ward and Tse, 1999), but its activity is not always measurable (Gutierrez et al., 1992); its protein has not been detected in crude homogenates from rat kidney (Valdés et al., 2000). Additionally, a novel concentrative nucleoside transporter activity, termed N4, has been described in human kidney, but still remains to be identified at the molecular level (Gutierrez and Giacomini, 1993).
The presence of equilibrative transporters (both ENT1 and ENT2) in absortive epithelial cells suggests the possibility of a transepithelial, vectorial transfer of nucleosides (Williams et al., 1989; Mangravite et al., 2003a). This hypothesis is controversial, however, since the intracellular metabolism of nucleosides appears too fast to allow such a flow from the apical to the basal membrane. Concentrative transporters seem to be restricted to the apical membrane of polarized epithelial cells (Patil and Unadkat, 1997; Ward and Tse, 1999), but there remains some controversy about the localization of equilibrative transporters (Trimble and Coulson, 1984; Doherty and Jarvis, 1993; Williams et al., 1989). The use of fluorescently tagged nucleoside transporters has not produced unequivocal results, since hCNT1 seems restricted to the apical membrane (Lai et al., 2002) and hENT2 to the basolateral domain (Mangravite et al., 2003b); hENT1 was described in the former report as being localized in the basolateral membrane and in the latter as being in both the apical and the basolateral membranes.
To date, the regulation of nucleoside transporters in epithelia has not been studied in depth. Nucleoside transport is sensitive to substrate availability in the small intestine. rCNT1 protein levels and activity are increased during fasting (Valdés et al., 2000), and this regulation is exerted, at least partially, by nucleosides, since the administration of a semipurified, nucleoside-free diet induced an increase in jejunal CNT1 expression and activity in rats (Valdés et al., 2000). The high sensitivity of CNT1 to nutrient availability may have clinical relevance, since it is involved in the uptake of most fluoropyrimidines used in cancer treatment (Pastor-Angalda et al., 1998; Baldwin et al., 1999), and gemcitabine uptake is enhanced in brush border vesicles from fasted rats (Valdés et al., 2000), although this drug is not administered orally. Endocrine regulation of these transporters in intestinal cells has only been reported once, where it was shown that glucocorticoids, insulin, and epidermal growth factor increase CNT2 activity in the rat small intestine–derived cell line IEC-6 (Jakobs et al., 1990).
In the present study, we have fully characterized the expression pattern of nucleoside transporters in IEC-6 cells. We have also shown that glucocorticoids, well-known differentiation agents for intestinal cells, increase CNT2 expression and activity, while epidermal growth factor (EGF) and transforming growth factor (TGF) , potent mitogens for enterocytes, do not affect concentrative transport but instead induce the expression and activity of ENT1, an effect mimicked by another enterocyte proliferative stimulus such as epithelial wounding. These results may be important for the improvement of nucleoside-derived drug delivery in anti-tumoral and anti-viral therapies.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
were from Sigma-Aldrich. All other reagents were of analytical grade.
Cell Culture and Treatments
IEC-6 cells (derived from crypt cells of the rat small intestine) were cultured in DMEM supplemented with 5% (by volume) FCS (or 0.2% BSA in some treatments), 1 mM sodium pyruvate, 4 mM glutamine, 0.1 U/ml bovine insulin, and a mixture of antibiotics and antimicotics. For dexamethasone treatment, cells were kept overnight in a serum-free, BSA-containing medium, and then dexamethasone was added at a final concentration of 100 nM for 24–48 h. Transport of 1 µM guanosine was then measured and protein and RNA extracts were obtained. Protein extracts were prepared in a lysis buffer containing 0.3 M sucrose, 25 mM imidazole (pH 7.2), 1 mM EDTA, aprotinin (2 µg/ml), leupeptin (10 µM), and AEBSF (1 mM). A 30-µg aliquot was used for analysis of rCNT2 protein by Western blot using a monospecific polyclonal rabbit antibody characterized elsewhere (Valdés et al., 2000). RNA extracts taken at different time points were prepared with the SV Total Isolation System (Promega) according to the manufacturer's instructions.
For EGF and TGF- treatments, cells were also serum deprived overnight and then either EGF (final concentration 20 ng/ml) or TGF- (10 ng/ml) was added. In some experiments, the ERK1/2 inhibitor PD98059 or the JNK1/2/3 inhibitor SP600125 was added at a final concentration of 10 µM and 20 µM, respectively, 30 min before growth factor addition. The epithelial wounding model (McCormack et al., 1992; Ciacci et al., 1993) consisted of a series of parallel cuts performed with a razor blade in the monolayer of cells (50–70 cuts per 2 cm2 dish), which had been deprived of serum for 12 h; PD98059 was also added to some dishes under the same conditions as stated before.
Measurement of Transport Activity
Nucleoside transport activity was measured at a substrate concentration of 1 µM for all nucleosides and a specific activity of 30 Ci/mmol (for uridine), 15 Ci/mmol (for guanosine), or 21.5 Ci/mmol (for cytidine), in the presence of either 137 mM sodium chloride or 137 mM choline chloride, as described elsewhere (del Santo et al., 1998). Uridine was used as a common permeant for CNTs and ENTs (ENT1 and ENT2 activities were discriminated using 1 µM nitrobenzyl-thioinosine [NBTI]), and, since CNT3 was shown to be absent, sodium-dependent guanosine transport could be used as a CNT2-specific measure and sodium-dependent cytidine transport as a CNT1-specific measure. The uptake medium also contained 5.4 mM KCl, 108 mM CaCl2, 1.2 mM MgSO4, and 10 mM HEPES, (pH 7.4). Transport measurement was stopped after 1 min incubation by washing the cells twice with 2 ml of a cold buffer containing 137 mM NaCl and 10 mM Tris-HEPES, pH 7.4. Cells were then dissolved in 100 ml of 100 mM NaOH, 0.5% Triton X-100, and aliquots were taken for protein determination (Bradford assay; BioRad Laboratories) and for radioactivity measurements.
Reverse Transcription and RT-PCR
1 µg of total RNA was used for cDNA synthesis using the TaqMan Reverse Transcription System (Applied Biosystems), according to the manufacturer's instructions. Oligonucleotide primer sequences for RT-PCR were as follows: CNT1 forward 702–725 (tttgcaggcatctgtgtgttcct) and reverse 1272–1295 (caacgcacaaggggcggccatgac); CNT2 forward 776–799 (gctcaaaggccagagcagctgatc) and reverse 1442–1445 (cagcttcactccctccttgctctt); ENT1 forward 5–25 (atgacaaccagtcacc) and reverse 1352–1375 (tccttcttgttaagggcacttgtg); ENT2 forward 356–376 (aacaactgggtgacactgctgt) and reverse 1379–1400 (ggctacttcgtgtctctcacca). RT-PCR was performed in a Thermocycler (Applied Biosystems), and the polymerase used was TaqDNA polymerase (Promega).
Real-time RT-PCR
The primers and probes used to amplify cDNA by real-time RT-PCR were designed using Primer Express software and the sequences employed were as follows: rGAPDH forward 30–50 (gatggtgaaggtcggtgtcaa), reverse 115–91 (caaatgtccacttgtcacaagagaa), probe 70–89 (ccgcctggtcaccagggctgc); rCNT2 forward 785–803 (tgcgggaatctgcatgtt), reverse 854–836 (ctccagctcaccgcactgt), probe 805–831 (atcctcatcctctttgcctgctccaaa); rENT1 forward 765–785 (gtgaaggagaggagccaagag), reverse 836–817 (tgttggcgggtagagagagagttg), probe 807–789 (accccagattcctctcttc); and rENT2 forward 923–943 (ggcccaactctggatcttgac), reverse 990–979 (cctggcttctgtggttcct), probe 968–945 (ctccagctccttctctg). Real-time monitoring of PCR amplification of cDNAs was performed with the TaqMan Universal Master Mix (Applied Biosystems) using 150 nM probe and 700 nM each primer, in the ABI Prism 7700 Sequence Detection System (Applied Biosystems). The relative quantification of gene expression was performed according to the manufacturer's instructions using rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control. The threshold cycle (CT) is defined as the cycle number at which the fluorescence corresponding to the amplified PCR product is first detected. The results are given as PCR arbitrary units of each transporter after normalizing the mRNA levels of these genes to the GAPDH expression levels.
Analysis of ERK1/2 Phosphorylation
IEC-6 cells were incubated under the various conditions tested and then treated with Triton lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 100 mM NaF, 10 mM EDTA, 10 mM Na4P2O7, 2 mM Na3VO4, 1% Triton X-100, 2 µg/ml aprotinin, 10 µM leupeptin, and 1 mM AEBSF) at selected times for the first 30 min after treatment. Extracts were then centrifuged for 5 min at 12,000 rpm, their protein contents measured, and 15 µg or 40 µg of the supernatants used for analysis of total or active ERK1/2, respectively, by Western blot.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
60% at 24 h and near to 100% at 48 h). Although much lower in absolute value, equilibrative transport of guanosine was also increased by a similar proportion in response to dexamethasone. In accordance with these data, CNT2 mRNA and protein levels were also increased by dexamethasone treatment (three- and fourfold at 24 and 48 h, respectively), as shown by the results obtained with real-time RT-PCR (Fig. 2 B) and Western blot (Fig. 2 C). Dexamethasone treatment also increased the levels of CNT1 mRNA and activity, although this latter effect (measured as sodium-dependent cytidine transport) remained at almost undetectable levels (2.9 ± 0.3 vs. 1.5 ± 0.1, in the presence or absence of dexamethasone, respectively), corresponding to <2% of the activity observed for CNT2.
|
(unpublished data). Instead, treatment with either growth factor resulted in an increase in sodium-independent uridine transport. When analyzed in more detail, only the NBTI-sensitive component of equilibrative uridine transport (i.e., ENT1 activity) was responsible for this increase (Fig. 3 A), while the NBTI-resistant component (i.e., ENT2 activity) was unaltered by either treatment, at least at the growth factor concentrations used (Fig. 3 B). By real-time RT-PCR, it could be shown that only ENT1 mRNA levels were increased in response to growth factor addition, while the levels of ENT2 mRNA remained constant (Table I).
|
|
on ENT1 expression and activity were mimicked by a model of epithelial wounding (Fig. 4). Again, an increase in ENT1, but not in ENT2 (not depicted), activity was detected 10 h after injuring the cells (Fig. 4 A), and this change was paralleled by an increase in ENT1 mRNA levels (Fig. 4 B). Since all these proliferative stimuli are known to activate the mitogen-activated protein (MAP) kinase pathway in the intestine, the possible involvement of these protein kinases in this ENT1 response was tested. Both growth factor incubation and epithelial wounding resulted in an increase in the phosphorylated form of ERK1/2 as early as 5–10 min after the beginning of the stimulus (Fig. 3 C and Fig. 4 C). Blocking the activity of ERK1/2 with the inhibitor PD98059 resulted in a loss of the effect on ENT1 activity in response to either growth factors (Fig. 3 A) or epithelial wounding (Fig. 4 A). The response of ENT1 mRNA levels, however, was different in both models. PD98059 caused a decrease in the basal levels of ENT1 mRNA in IEC-6 cells (Table I). However, while it completely suppressed the induction of ENT1 mRNA in the epithelial injury model (Fig. 4 B), the threefold induction of ENT1 mRNA in response to EGF and TGF- treatments was unaltered (Table I). JNK1/2/3 inhibition had a different effect: the addition of the inhibitor SP600125 induced an increase in ENT1 mRNA levels and activity (Table I), but had no effect on the response to either growth factor.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
). The human intestine expresses both concentrative and equilibrative nucleoside transporters (Chandrasena et al., 1997; Patil and Unadkat, 1997); the sodium-dependent nucleoside transporters are distributed along a longitudinal gradient, with higher activities in the most proximal regions of the small intestine (Ngo et al., 2001). It has recently been suggested that such a dual distribution of concentrative and equilibrative transporters exists in intestinal epithelial cells (Williams et al., 1989), although in renal epithelial cells this pattern is less clear (Lai et al., 2002; Mangravite et al., 2003b). This differential location of nucleoside transporters at both membranes supports the suggestion of a transepithelial flux of nucleosides, as already shown for some substrates in kidney cells (Mangravite et al., 2003a; Lai et al., 2002), although the rapid intracellular metabolization of nucleosides argues against this possibility. Thus, the need for good absorptive cell models to study nucleoside transport is evident.
The expression pattern of nucleoside transporters in the rat intestinal epithelial cell line IEC-6 has been poorly characterized (Jakobs et al., 1990). In this study, we have performed a full characterization of this cell model, confirming the existence of a purine-preferring, sodium-dependent activity that is consistent with the expression of CNT2, shown by RT-PCR and Western blot. Furthermore, we have demonstrated the existence of two equilibrative activities, both NBTI sensitive and resistant, consistent with the expression of ENT1 and ENT2, respectively. Although some CNT1 mRNA and protein can be detected by RT-PCR and Western blot, no significant activity could be measured using cytidine as substrate.
The acquisition of intestinal digestive and absorptive properties is intimately linked to the degree of differentiation. Thus, immature crypt cells express few mature enterocytic features, such as sucrase–isomaltase complex activity or even a well-organized brush border at the luminal surface (Quaroni et al., 1979; Isselbacher, 1974). These functions are acquired during the migration of the cells along the crypt–villus axis. The IEC-6 cell line is derived from crypt cells and so it shares many of the undifferentiated characters typical of the immature enterocyte (Quaroni et al., 1979). One of the best characterized maturation agents for intestinal cells are glucocorticoids (Blake and Henning, 1983), either directly or through the stimulation of cell–cell and cell–matrix interactions (Louvard et al., 1992; Simo et al., 1992). IEC-6 cells also respond to glucocorticoids with cell cycle withdrawal and ultrastructural changes (Quaroni et al., 1999), although no induction of brush border enzymatic activities could be detected, possibly due to the failure to establish contacts with the basement membrane or with mesenchymal cells. Glucocorticoids did not elicit the appearance of sodium-dependent glucose transport in IEC-6 cells either (Inui et al., 1980), but they seem to increase the levels of previously expressed transporters (Iannoli et al., 1998). In agreement with this latter report, we have shown that dexamethasone treatment of IEC-6 cells clearly increases both CNT2 expression and activity and also boosts CNT1 expression. The fact that CNT1 activity is not measurable even after dexamethasone treatment might be explained by a failure to insert the transporter molecules into the membrane correctly. Intracellular trafficking of CNT1 molecules is much more complex than that of CNT2 and most of the protein remains in intracellular structures (Duflot et al., 2002). Our results would thus support a direct role of glucocorticoids in the regulation of some mature enterocyte features in IEC-6 cells and are in agreement with our previous results showing that CNT expression is directly dependent upon glucocorticoid regulation (del Santo et al., 2001).
A very different response is observed after EGF or TGF- treatment of IEC-6 cells. EGF and TGF- are among the most potent proliferative agents for intestinal epithelial cells, both in vivo (Koyama and Podolsky, 1989; Hirano et al., 1995; Dignass et al., 1996) and in vitro (Rokutan et al., 1994; Riegler et al., 1996; Dionne et al., 1998). The proliferation induced by TGF- seems to be regulated by the autocrine production of TGF-. Thus, it is initially self-maintained, but is ultimately down-regulated by the production of the growth-arresting TGF-ß signal (Suemori et al., 1991). Treatment of IEC-6 cells with either EGF or TGF- had little effect on concentrative nucleoside transporters, but elicited a more than twofold increase in ENT1 activity and mRNA levels. This result is in clear support of a role for ENT1 as the main nucleoside purveyor for cell proliferation, as previously reported in macrophages (Soler et al., 2001).
Epithelial intestinal cell proliferation can be elicited in vivo by mucosal damage (Feil et al., 1987; Lacy, 1988), and an in vitro model of epithelial wounding has been developed in IEC-6 cells (McCormack et al., 1992; Ciacci et al., 1993). Many growth factors and cytokines have been shown to mediate the proliferative response to mucosal wounding, such as TGF-, TGF-ß, EGF, hepatocyte growth factor, acidic and basic fibroblast growth factors, and IL-1ß (Dignass and Podolsky, 1993; Dignass et al., 1994), although EGF does not seem to reduce chemotherapy-induced intestinal injury (Huang et al., 2002). In vitro wounding of IEC-6 cells also resulted, as in the treatments with EGF or TGF-, in an increase in ENT1 activity, but without any effect on concentrative transporters. Thus, both proliferative stimuli induce the equilibrative transport that has been reported previously to be present in the basolateral membrane of the epithelial cell (Lai et al., 2002; Mangravite et al., 2003b), presumably to ensure nucleoside supply for proliferation that would have been derived from the bloodstream had this stimulus occurred in vivo. In this context, it has been shown that supplementation of parenteral nutrition formulae with nucleosides or nucleotides greatly ameliorates intestinal mucosa atrophy caused by total parenteral nutrition (Iwasa et al., 2000).
Both TGF- and epithelial injury are known to stimulate the mitogen-activated protein (MAP) kinase cascade in IEC-6 cells (Dionne et al., 1998; Oliver et al., 1994; Göke et al., 1998). In our model, both kinds of stimuli increased the phosphorylation level of ERK1/2, and, as might have been expected, blocking of ERK1/2 activity resulted in a loss of the effect of wounding on ENT1 mRNA and activity. However, the same effect was not observed after growth factor treatment, where only a decrease in ENT1 activity, but not in mRNA expression level, was observed. So, while the wounding effects on ENT1 can be explained by an increase in its gene transcription rate mediated by ERK1/2, the effects triggered by EGF and TGF must use a different signal transduction pathway. This alternate pathway is not mediated by JNK, since its inhibition had no effect on growth factor induction of ENT1 expression. Although we have tested a battery of different possible pathways (PI3 kinase, PKC, PKA, Tor kinase, and p38; unpublished data), the identity of this mediator still remains elusive.
In conclusion, induction of differentiation of IEC-6 cells results in an increase in the expression and activity of mature enterocyte nucleoside transporters such as CNT2 (and to a lesser extent CNT1), concentrative transporters located at the apical membrane of the enterocyte where they participate in the absorption of dietary nucleosides. In contrast, a proliferative signal such as epithelial wounding or growth factor exposure induces an increase in the expression and activity of ENT1, a basolateral nucleoside transporter, probably involved in the release of absorbed nucleosides or, as in this case, in the uptake of circulatory nucleosides to support the increased proliferation rate of these cells.
|
ACKNOWLEDGMENTS |
|---|
David C. Gadsby served as editor.
Submitted: 30 April 2004
Accepted: 7 September 2004
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
and ß. Gut. 38:687–693.- and EGF-stimulated IEC-6 cell growth. Biochem. Biophys. Res. Commun. 242:146–150.[CrossRef][Medline] and ß in rat intestinal epithelial cells. J. Clin. Invest. 83:1768–1773.[Medline] increases tyrosine phosphorylation of microtubule-associated protein kinase in a small intestinal crypt cell line (IEC-6). Biochem. J. 303:455–460.[Medline]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Govindarajan, C. J. Endres, D. Whittington, E. LeCluyse, M. Pastor-Anglada, C.-M. Tse, and J. D. Unadkat Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes Am J Physiol Gastrointest Liver Physiol, September 1, 2008; 295(3): G570 - G580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Liao, M. J. Alman, E. S. Vanzant, E. D. Miles, D. L. Harmon, K. R. McLeod, J. A. Boling, and J. C. Matthews Basal Expression of Nucleoside Transporter mRNA Differs Among Small Intestinal Epithelia of Beef Steers and Is Differentially Altered by Ruminal or Abomasal Infusion of Starch Hydrolysate J Dairy Sci, April 1, 2008; 91(4): 1570 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Rose and I. R. Coe Physiology of Nucleoside Transporters: Back to the Future. . . . Physiology, February 1, 2008; 23(1): 41 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Govindarajan, A. H. Bakken, K. L. Hudkins, Y. Lai, F. J. Casado, M. Pastor-Anglada, C.-M. Tse, J. Hayashi, and J. D. Unadkat In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1809 - R1822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Errasti-Murugarren, M. Pastor-Anglada, and F. J. Casado Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs J. Physiol., August 1, 2007; 582(3): 1249 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Aymerich, F. Foufelle, P. Ferre, F. J. Casado, and M. Pastor-Anglada Extracellular adenosine activates AMP-dependent protein kinase (AMPK) J. Cell Sci., April 15, 2006; 119(8): 1612 - 1621. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
, P < 0.05, 